Sign in
Stories
Egle Therapeutics Bolsters Leadership Team
Share
AB-2100 Phase 1/2 Trial Initiated
AI-Powered Antigen Research Partnership
Adagene Advances Clinical Collaboration
CDR-Life's FDA Clearance for Precision I...
Cue Biopharma to Present Corporate Updat...
France's CAR-T Cell Therapy Market
Overview
API
Egle Therapeutics enhances leadership team with Monica Gostissa as CSO and Reno Winter as CTO. Gostissa leads research, Winter oversees manufacturing for regulatory T cell therapies in oncology and autoimmune diseases.
Ask a question
How does the expertise of Gostissa and Winter align with Egle's goals in oncology and autoimmune diseases?
How might the new leadership team impact Egle Therapeutics' research and development pipeline?
What specific advancements in regulatory T cell therapies can be expected from Egle's focus?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Dec 2023
Jan 2024
Feb 2024
Coverage